EC=Endometrial Cancer, CRC=Colorectal Cancer, ESO=Esophageal Cancer,
HNSCC = Head & Neck Squamous Cell Carcinoma, cHL = classical Hodgkin Lymphoma,
PMBCL = primary Mediastinal B-cell Lymphoma, NSCLC = Non-small cell lung carcinoma,
RCC = renal cell carcinoma, TNBC = triple negative breast cancer, dMMR=dMMR=mismatch repair deficient; BCG=Bacillus Calmette-Guerin; MSI-H=microsatellite instability-high.
* Clinical significance has not been established.
† Indications authorized as of April 2023.
References: 1. Merck Canada Inc. KEYTRUDA® Product Monograph. April 19, 2023.
2. Data on file – IQVIA June 2022. Merck Canada Inc.
3. Health Canada. Notice of compliance database. Available at: https://health-products.canada.ca/noc-ac/index-eng.jsp. Accessed October 12, 2022.
4. Health Research Foundation (via Newswire). Honourees Celebrated at 2017 Health Research Foundation Research Awards Gala. Available at: https://www.newswire.ca/news-releases/honourees-celebrated-at-2017-health-research-foundation-research-awards-gala-659452753.html. Accessed October 12, 2022.
This site is intended for Canadian healthcare professionals.